In a phase 2 study of G/GEJ cancer patients who received ≥ 2 lines of prior therapy, targeting the PD-1 receptor with pembrolizumab benefited a minority of patients, with approximately 80% of patients rapidly progressing, and a response rate of 15.5% in patients with PD-L1-positive tumors (CPS ≥ 1; per 22C3 assay) [16]. The gene discussed is CD274; the disease is cancer.